Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.
PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.
|Study Design:||Primary Purpose: Supportive Care|
|Official Title:||Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia|
- Frequency of cytopemic response [ Designated as safety issue: No ]
|Study Start Date:||March 2002|
|Primary Completion Date:||May 2005 (Final data collection date for primary outcome measure)|
- Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine.
OUTLINE: This is a multicenter study.
Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 4 months for 1 year and then every 6 months for 9 years.
PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00031980
|United States, New York|
|Roswell Park Cancer Institute|
|Buffalo, New York, United States, 14263-0001|
|Study Chair:||Maria R. Baer, MD||University of Maryland Greenebaum Cancer Center|